This week in Neurosurgery
Nov 18, 2026
Surgiceloplasty versus watertight duraplasty after decompressive craniectomy for traumatic brain injury: A randomized controlled non-inferiority trial.
In 248 patients undergoing decompressive craniectomy for brain trauma, an oxidized cellulose onlay was non-inferior to watertight duraplasty for complications, matched three-month function, and shortened surgery by about 40 minutes.
Journal of Clinical Neuroscience · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: a cellulose onlay holds its own against watertight duraplasty after decompressive craniectomy, duraplasty adds morbidity without clear benefit in pediatric Chiari decompression, and the bedside shunt tap proves safe and specific for malfunction.
Welcome to This Week in Neurosurgery. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
The week's strongest evidence is a randomized trial in the Journal of Clinical Neuroscience from Pratap Singh and colleagues [1]. It is an evaluator-blinded non-inferiority trial at a single level-1 trauma centre registered in India, and it enrolled 248 patients under 60 who underwent decompressive craniectomy for traumatic brain injury. Patients were randomized to standard watertight duraplasty or to a simple onlay of oxidized regenerated cellulose, which the authors call Surgiceloplasty. Just under three in five patients had severe injury. The primary outcome was at least one prespecified complication during the index admission, with a fifteen-point non-inferiority margin. Complications occurred in about 18 percent of the duraplasty group and about 19 percent of the onlay group, a difference of under two points, so non-inferiority was met. Infective complications were similar at around 8 percent in each arm. The onlay shortened surgery by roughly 40 minutes. Three-month function was comparable, with about half of patients in each group reaching a favourable outcome and about a third dying or remaining in the worst outcome category. The main limitation is a single centre, a younger population and complications counted only during admission. The authors call for multicentre confirmation, but this is randomized evidence that a simpler closure is not inferior.
A meta-analysis in the Journal of Neurosurgery: Pediatrics from Nischal and colleagues asks a related question about whether dural reconstruction earns its operative time, here in pediatric Chiari malformation type I [2]. The authors pooled 26 comparative studies covering nearly six thousand children treated with posterior fossa decompression either with or without duraplasty. Clinical improvement was about 71 percent without duraplasty and 80 percent with it, a difference that was not statistically significant. Syrinx improvement, Chicago Chiari Outcome Scale scores and reoperation also showed no significant difference. CSF-related morbidity was roughly half as frequent without duraplasty, and adding the graft lengthened surgery by about an hour and the hospital stay by about a day. Graft type made no consistent difference. In meta-regression, cohorts with more syrinx showed greater improvement after duraplasty, a study-level signal that does not identify individual children who benefit. Most included studies were retrospective with moderate to serious risk of bias, and overall certainty was graded moderate. Sensitivity analyses limited to strictly defined congenital cohorts and to studies using intraoperative ultrasound reproduced the main findings. Together with the craniectomy trial, this week's evidence questions the added value of formal dural reconstruction in two different settings.
In Neurosurgery, Basaran and colleagues report an individual patient data meta-analysis on supratotal resection in IDH-mutant grade 2 and 3 gliomas [3]. Survival data for 876 patients were reconstructed from published Kaplan-Meier curves across studies from 2010 to 2025, comparing resection beyond the MRI-defined border with total resection. In grade 2 gliomas, sixteen-year overall survival was about 96 percent after supratotal resection versus about 67 percent after total resection, a restricted mean survival gain of about two years. The benefit differed by histology. In grade 2 astrocytomas the gain was close to 33 months, while in grade 2 oligodendrogliomas the difference was about 7 months and not statistically significant, with too few deaths for stable estimates. The main limitation is that the data are reconstructed from published curves of observational series, so patients selected for supratotal resection may differ from those who were not, and confounding cannot be excluded. The authors conclude that supratotal resection is the preferred strategy when functionally feasible. The evidence is strongest for astrocytomas and remains uncertain for oligodendrogliomas, and no randomized comparison exists.
Now, four in brief.
Extent of resection also anchors a patient-level systematic review of WHO grade 2 meningioma in the Journal of Neuro-Oncology from Qiu and colleagues [4]. Pooling 640 patients from 203 published studies across three decades, the authors found that just over half of patients progressed or recurred. Subtotal resection nearly doubled the progression hazard compared with gross-total resection. After subtotal resection, adjuvant radiotherapy was associated with roughly a two-thirds lower progression hazard, a finding that held in landmark analysis. After gross-total resection, the radiotherapy association was not definitive, and radiosurgery versus fractionated treatment showed no significant difference. These are case-level data from published reports, prone to selection and reporting bias.
In the Journal of Clinical Neuroscience, Manalil and colleagues pooled 13 mostly retrospective studies of middle meningeal artery embolization for chronic subdural hematoma, covering about fifteen hundred patients [5]. Proximal versus distal penetration, standalone coiling, and single versus multiple branch embolization were not significantly associated with radiographic success or need for rescue treatment. The point estimate favoured distal penetration for radiographic success, but the authors state this does not establish superiority. Heterogeneous outcome definitions, short follow-up and few studies make these null results weak, and the authors call for multicentre studies with core-lab adjudication.
In World Neurosurgery, a single-centre retrospective cohort from Liang and colleagues followed 218 patients after flow diversion who stopped aspirin monotherapy at one year or continued it longer [6]. Over a median of about two and a half years, there were only eight late ischemic or hemorrhagic events, and the composite endpoint did not differ significantly between groups. All five late hemorrhages, including one severe intracerebral bleed, occurred in the prolonged-therapy group, and occlusion rates were similar. With so few events and no randomization, the authors present this as hypothesis-generating for prospective study.
Also in Neurosurgery, Harper and colleagues assessed the ventricular shunt tap in 213 taps across 94 patients at one institution [7]. For proximal obstruction, specificity was about 99 percent and sensitivity about 84 percent. For distal obstruction, specificity was 100 percent and sensitivity about 78 percent. An opening pressure of 0.5 centimetres of water or less and distal runoff of 9.5 or less were the best thresholds. No tap-related complications or infections were found. The design is retrospective, and patients not operated on were classified by thirty-day clinical course.
Three quick signals.
In the Journal of Neurosurgery, Greenberg and colleagues report 50 patients with neuralgic amyotrophy not recovering by six months who underwent 59 nerve transfers by a single surgeon [8]. Over 85 percent of transfers had a good outcome at two years, disability scores improved substantially, and complications occurred in 7 percent without donor weakness. This is a retrospective single-surgeon series without controls.
Also on nerve reconstruction, Cua and colleagues in the Journal of Clinical Neuroscience reviewed hypoglossal-facial anastomosis after vestibular schwannoma surgery across 48 studies and 866 patients [9]. Facial function improved in about nine in ten patients, and just under half of patients reached House-Brackmann grade three or better. Tongue hemiatrophy affected about a fifth of patients. The evidence is mostly uncontrolled case series.
In the Journal of Neurosurgery: Spine, Rezner and colleagues compared anterior cervical discectomy and fusion in patients aged 75 and older with younger patients from a quality registry of 1,155 patients [10]. After matching 69 pairs, patient-reported outcomes were equivalent through two years. The older cohort was small and carefully selected.
Stepping back across this week's papers, most of the evidence comes from pooled retrospective series, reconstructed survival curves and single-institution cohorts, with one randomized trial standing apart. Several analyses report no significant difference, yet small event counts and heterogeneous definitions mean those null results cannot confirm equivalence. Where pooled observational data show large survival gains, the selection of patients for more extensive surgery remains an unmeasured explanation, and prospective comparisons are still missing for most of these questions.
If you only have time for one paper this week, make it the Surgiceloplasty trial [1]. It is the week's only randomized evidence, and it reopens whether watertight duraplasty after decompressive craniectomy is necessary at all.
That's your roundup for This Week in Neurosurgery. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Neurosurgery every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?